Johnson and Johnson 2009 Annual Report Download - page 21

Breakthrough solutions can
come from many sources.
Several significant scientific
collaborations and acquisitions
evidence a pursuit of the best
science to uncover these
solutions and improve the
odds of success for products
and patients in areas of high
unmet needs. (Also see story
on page .) These are a few
examples related to R&D
eorts in oncology and
infectious diseases:
Johnson & Johnson and
•
Tianjin Medical University
Cancer Hospital in China
established a partnership in
February . At the hospital,
tumor specimens are collected
from patients and catalogued,
Global growth and market
expansion of core brands
proved successful
pharmaceutical business
drivers in.
Several core brands in
three franchise areas—
Infectious Disease,
Immunology and
Neuroscience (see story on
page )—achieved regula-
tory milestones, broadening
the patient populations who
can benefit. These include
® (darunavir),
® (etravirine)
and ® (iniximab).

In early , the European
Commission approved
once-daily dosing of  mg
® (darunavir), a
protease inhibitor, with
low-dose ritonavir as part of
combination therapy in
treatment-naive adults (those
who have not previously taken
HIV medication). This approval
broadens the previous
indication of darunavir for
treatment-experienced
HIV-patients.
Following the U.S. Food
and Drug Administration’s
December approval of
®, co-administered
with ritonavir and other
antiretroviral agents, for the
treatment of HIV infection in
pediatric patients age  and up,
a lower-dose ( mg) formula-
tion of ® for pediatric
HIV patients was introduced in
the U.S. in February.






Applications were also
submitted in  other countries.
®
A non-nucleoside reverse
transcriptase inhibitor
(NNRTI), ®
(etravirine) is the first medica-
tion in the class to demonstrate
antiviral activity against
NNRTI-resistant virus. Nineteen
additional countries approved
the use of ® in
treatment-experienced
patients, including Brazil,
China, Croatia, Israel and Chile.
® is now approved
in  countries in Europe, the
Middle East & Africa (EMEA),
the Americas and Asia-Pacific.

An impressive example of the
strategy to address unmet
needs by investigating and
seeking approval for additional
indications—building a
“pipeline in a product”—
® (iniximab)
continues to meet the health
care needs of patients with a
number of inammatory
diseases involving the
immune system. These
include chronic, severe
plaque psoriasis, moderate
to severe rheumatoid
arthritis, active psoriatic
arthritis, moderate to severe
Crohn’s disease in adults and
children, moderate to severe
ulcerative colitis and active
ankylosing spondylitis.
® is available
in  countries and has
achieved approvals for 
indications. Worldwide,
® has been used
to treat more than  million
patients. It is part of a
growing immunology
portfolio that includes
other potentially versatile
compounds.
allowing scientists to identify
biomarkers that could help
personalize medicine and
advance cancer treatment.
Johnson & Johnson acquired
•
Cougar Biotechnology, Inc. in
July . Clinical trials are
under way on a compound for
the treatment of prostate
cancer, a disease that accounts
for  percent of cancer-related
deaths in the United States.
(See related feature on page
.)
In July
• , Tibotec
Pharmaceuticals entered into a
license and collaboration
agreement with Gilead
Sciences, Inc. for the develop-
ment and commercialization
of a new once-daily, fixed-
dose antiretroviral product.
In June
• , Tibotec, Inc.
announced a collaboration
with the Global Alliance for
TB Drug Development to
accelerate the discovery and
development of new drugs to
fight tuberculosis. Among
infectious diseases, TB is the
second most common cause
of adult deaths worldwide.
In May
• , Tibotec-Virco
Virology BVBA and Siemens
Healthcare Diagnostics Inc.
announced a licensing
agreement that will allow
Tibotec-Virco Virology BVBA
to develop a new research
technology platform to assist
with the development of
antivirals for the treatment
of hepatitis C virus (HCV).
More than  million
people worldwide are infected
with HCV, a virus that can
lead to serious and fatal
diseases of the liver.
Researchers from Johnson & Johnson
and Tianjin Medical University Cancer Hospital in China are pursuing
the best science to identify biomarkers that could help personalize
medicine and advance cancer treatment.
JOHNSON & JOHNSON 2009 ANNUAL REPORT 19
